Skip to main content
OncoTherapy Science, Inc. logo

OncoTherapy Science, Inc. — Investor Relations & Filings

Ticker · 4564 ISIN · JP3202150003 LEI · 529900CIAZCAIG781H52 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2023-06-27 Governance Information
Country JP Japan
Listing T 4564

About OncoTherapy Science, Inc.

https://www.oncotherapy.co.jp/en/

OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.

Recent filings

Filing Released Lang Actions
内部統制報告書－第22期(2022/04/01－2023/03/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act (金融商品取引法) in Japan. It details the company's framework, evaluation scope, and results regarding internal controls over financial reporting. Since this is a specific regulatory filing concerning internal control systems and does not fit into the other categories like 10-K (Annual Report) or ER (Earnings Release), it is classified as a Regulatory Filing.
2023-06-27 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO regarding the accuracy of the Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 2022
2023-06-27 Japanese
有価証券報告書－第22期(2022/04/01－2023/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, including consolidated and non-consolidated経営指標 (management indicators), balance sheets, and income statements for the fiscal year ending March 31, 2023. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau. FY 2023
2023-06-27 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of a Quarterly Report (第３四半期報告書). While it references a quarterly report, the document itself is a formal regulatory confirmation statement required by Japanese law to accompany the filing. Since it is a specific regulatory filing that does not fit into the primary financial report categories and serves as a formal regulatory submission, it is classified as a Regulatory Filing (RNS).
2023-02-13 Japanese
四半期報告書－第22期第3四半期(2022/10/01－2022/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the 22nd fiscal period, covering the period from October 1, 2022, to December 31, 2022. It contains detailed financial statements, management analysis (MDA), and business updates, which are characteristic of an Interim/Quarterly Report. It is not an announcement of a report (RPA) because it contains the full content of the report itself. Q3 2022
2023-02-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the Second Quarter Report (第２四半期報告書). While it references a quarterly report, the document itself is a formal regulatory filing confirming the accuracy of the financial statements for the period ending September 30, 2022. Since it is a specific regulatory filing required by Japanese law for financial reporting compliance and does not fit into the 'Interim/Quarterly Report' (IR) category (which would be the report itself) or other specific categories, it is best classified as a Regulatory Filing.
2022-11-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.